Sickle cell disease (SCD) is a prevalent inherited hemoglobin disorder encompassing a cluster of congenital hemolytic anemias, each distinguished by the prevalence of sickle hemoglobin (HbS) []. Anemia, predisposition to mainly bacterial infections and complications that include vaso-occlusive crisis (VOC) and delayed hemolytic transfusion reaction (DHTR) are its main features, with the two latter being responsible for the increased rates of morbidity and mortality despite the use of hydroxyurea as a standard of care [,]. The primary pathophysiological mechanism of the disease involves hemolysis resulting from the interaction of sickle cells with neutrophils, platelets, or endothelial cells in small blood vessels. Studies of small cohorts of SCD patients revealed complement activation, although the exact mechanism remains largely unknown. Therefore, it is important to predict the group of patients that could potentially benefit from complement inhibition. Eculizumab is the only complement inhibitor that has been used with beneficial results in DHTR and VOC to date [].
Numerous novel agents are currently undergoing clinical development or have been introduced into clinical practice. In addition, the attempts to reduce long-term complications and enhance quality of life continue. This Special Issue aims to delineate both our current understanding and future options in SCD.
All articles submitted to this Special Issue underwent a meticulous peer review process. Ultimately, two articles, two brief reports and one review were published. These five manuscripts are discussed below.
- (i)
- Forte and colleagues provided important data on the timely issue of COVID-19 and SCD, updating outcomes after two years of the pandemic [].
- (ii)
- Tsitsikas and colleagues presented the rate of dental extractions in SCD, providing up-to-date knowledge on an understudied complication [].
- (iii)
- Biswas and colleagues reviewed the role of mitochondria as an emerging consequential in SCD, highlighting pathophysiological and therapeutic challenges [].
- (iv)
- Kuo and colleagues reported that thromboprophylaxis reduced venous thromboembolism in SCD patients with central venous access devices, studying a large retrospective cohort [].
- (v)
- Gavriilaki and colleagues studied the immune response of adult SCD patients after their vaccination against COVID-19, providing the experience of a Greek center.
Considering the multi-faceted challenges of SCD, we hope that this Special Issue will inspire researchers and clinicians to continue their explorations into novel advances in this field [].
Author Contributions
All authors contributed equally to writing and editing this Editorial. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Varelas, C.; Tampaki, A.; Sakellari, I.; Anagnostopoulos, A.; Gavriilaki, E.; Vlachaki, E. Complement in Sickle Cell Disease: Are We Ready for Prime Time? J. Blood Med. 2021, 12, 177–187. [Google Scholar] [CrossRef] [PubMed]
- Vlachaki, E.; Gavriilaki, E.; Kafantari, K.; Adamidou, D.; Tsitsikas, D.; Chasapopoulou, E.; Anagnostopoulos, A.; Tsapas, A. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Hemoglobin 2018, 42, 339–341. [Google Scholar] [CrossRef] [PubMed]
- Vlachaki, E.; Andreadis, P.; Neokleous, N.; Agapidou, A.; Vetsiou, E.; Katsinelos, P.; Boura, P. Successful Outcome of Chronic Intrahepatic Cholestasis in an Adult Patient with Sickle Cell/ beta+ Thalassemia. Case Rep. Hematol. 2014, 2014, 213631. [Google Scholar] [PubMed]
- Tampaki, A.; Gavriilaki, E.; Varelas, C.; Anagnostopoulos, A.; Vlachaki, E. Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. Blood Rev. 2021, 48, 100805. [Google Scholar] [CrossRef] [PubMed]
- Castonguay, M.; Dakhallah, N.; Desroches, J.; Colaiacovo, M.L.; Jimenez-Cortes, C.; Claveau, A.M.; Berube, S.; Hafsaoui, A.Y.; Souza, A.; Tibout, P.; et al. COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic. J. Clin. Med. 2022, 11, 7361. [Google Scholar] [CrossRef] [PubMed]
- Ahmad, A.; Mihalca, D.; Stacey, B.; Samaee, S.; Mehta, D.; Hibbs, S.; Freeman, T.; Chatterjee, B.; Ali, E.; Cheng, L.; et al. Rate of Dental Extractions in Patients with Sickle Cell Disease. J. Clin. Med. 2022, 11, 6174. [Google Scholar] [CrossRef] [PubMed]
- Akhter, M.S.; Hamali, H.A.; Rashid, H.; Dobie, G.; Madkhali, A.M.; Mobarki, A.A.; Oldenburg, J.; Biswas, A. Mitochondria: Emerging Consequential in Sickle Cell Disease. J. Clin. Med. 2023, 12, 765. [Google Scholar] [CrossRef] [PubMed]
- Forte, S.; De Luna, G.; Abdulrehman, J.; Fadiga, N.; Pestrin, O.; Pham Hung d’Alexandry d'Orengiani, A.L.; Aneke, J.C.; Guillet, H.; Budhram, D.; Habibi, A.; et al. Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study. J. Clin. Med. 2022, 11, 1193. [Google Scholar] [CrossRef] [PubMed]
- Varelas, C.; Gavriilaki, E.; Sakellari, I.; Klonizakis, P.; Koravou, E.E.; Christodoulou, I.; Mavrikou, I.; Kourelis, A.; Chatzopoulou, F.; Chatzidimitriou, D.; et al. Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center. J. Clin. Med. 2022, 11, 937. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).